U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Oncology Center of Excellence
  5. OCE Public Presentations
  1. Oncology Center of Excellence

OCE Public Presentations

FDA-ASCO 2024 Graphic Element

FDA Oncology Center of Excellence experts regularly join colleagues in clinical oncology and hematologic malignancies to participate in panel discussions, give talks on regulatory topics, or present research findings.


American Society of Clinical Oncology 2024 Annual Meeting 

OCE experts will present at the following ASCO Annual Meeting sessions at the McCormick Convention Center in Chicago and online. Times listed are Central Time (CT).

Friday, May 31: 2:45-3:45 pm CT, Hall A—Case-based Panel: Multicancer Detection: Is It Ready for Prime Time? Title: The Regulatory Perspective: Hurdles to Overcome. OCE speaker: Jamie Brewer (presentation and panelist).

Sunday, June 2

9:45-10:45 am CT, Hall B1—Education session: Integrating Immunotherapy into Early-Stage Lung Cancer. Title: Too Many Options: Assessing the Best Trial Designs. OCE speaker: Bernardo Goulart (presentation and panelist). 

9 am-12 pm CT—Poster Session, Quality Care/Health Services Research. 

  • Project Facilitate: An analysis of the increased utilization in the oncology single patient expanded access pathway. Mitchell Chan, Abstract 11029
  • Patient-reported outcomes corresponding to most common symptomatic adverse events in lung cancer clinical trials. Erica Horodniceanu, Abstract 11103 
  • Under-representation of Asian Americans, and Native Hawaiians, and other Pacific Islanders in cancer therapeutic clinical trials that led to the FDA approvals in 2010-2022. Ruby Leong, Abstract 11026 

1:30-4:30 pm CT—Poster Session, Lung Cancer – Non-Small Cell Metastatic: FDA Analysis of Immune Checkpoint Inhibitors in Combination with Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors in the Second-line Treatment of Patients with Advanced Non-Small Cell Lung Cancer. Justin Malinou, Abstract 8595 

Tuesday June 4

9 am-12 pm CT—Poster Session, Quality Care/Health Services Research. Impact of the COVID-19 pandemic mitigation strategies on cancer treatment trials: A meta-analysis of industry and NCI studies. Timil Patel (co-author on behalf of ASCO/Friends Protocol Adherence Task Force), Abstract 11021 

ASCO Abstracts - Online Publication

  • Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals During COVID-19. Timil Patel, e13802
  • Enrollment of older adults in clinical trials for oncology indications, 2010-2020: An evaluation by the FDA. Felice Yang, e23029
  • FDA Analysis of representation of Indian Americans and Indians in cancer clinical trials leading to approval from 2010 to 2022. Geetika Srivastava, e13779 

Past Events


Additional Information

Back to Top